New antiplatelet therapies for acute coronary syndromes

Jonathan D. Rich; Stephen D. Wiviott

doi:10.1007/BF02938379

New antiplatelet therapies for acute coronary syndromes

Jonathan D. Rich, Stephen D. Wiviott^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Platelets play a central role in the pathophysiology of acute coronary syndromes (ACS). Dual antiplatelet therapy has resulted in significant advances in the treatment of ACS; however, ACS remains an important cause of morbidity and mortality. Important limitations exist among the current antiplatelet agents and therefore a pressing need for the development of improved antiplatelet agents exists. Three antiplatelet agents currently under investigation (prasugrel, AZD6140, and cangrelor) in clinical trials for the treatment of ACS appear promising.

Original language	English (US)
Pages (from-to)	303-311
Number of pages	9
Journal	Current Cardiology Reports
Volume	9
Issue number	4
DOIs	https://doi.org/10.1007/BF02938379
State	Published - Jul 2007

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1007/BF02938379

Cite this

@article{29a0382d5adb4699b1a8c98435205ad4,

title = "New antiplatelet therapies for acute coronary syndromes",

abstract = "Platelets play a central role in the pathophysiology of acute coronary syndromes (ACS). Dual antiplatelet therapy has resulted in significant advances in the treatment of ACS; however, ACS remains an important cause of morbidity and mortality. Important limitations exist among the current antiplatelet agents and therefore a pressing need for the development of improved antiplatelet agents exists. Three antiplatelet agents currently under investigation (prasugrel, AZD6140, and cangrelor) in clinical trials for the treatment of ACS appear promising.",

author = "Rich, {Jonathan D.} and Wiviott, {Stephen D.}",

year = "2007",

month = jul,

doi = "10.1007/BF02938379",

language = "English (US)",

volume = "9",

pages = "303--311",

journal = "Current Cardiology Reports",

issn = "1523-3782",

publisher = "Current Medicine Group",

number = "4",

}

TY - JOUR

T1 - New antiplatelet therapies for acute coronary syndromes

AU - Rich, Jonathan D.

AU - Wiviott, Stephen D.

PY - 2007/7

Y1 - 2007/7

N2 - Platelets play a central role in the pathophysiology of acute coronary syndromes (ACS). Dual antiplatelet therapy has resulted in significant advances in the treatment of ACS; however, ACS remains an important cause of morbidity and mortality. Important limitations exist among the current antiplatelet agents and therefore a pressing need for the development of improved antiplatelet agents exists. Three antiplatelet agents currently under investigation (prasugrel, AZD6140, and cangrelor) in clinical trials for the treatment of ACS appear promising.

AB - Platelets play a central role in the pathophysiology of acute coronary syndromes (ACS). Dual antiplatelet therapy has resulted in significant advances in the treatment of ACS; however, ACS remains an important cause of morbidity and mortality. Important limitations exist among the current antiplatelet agents and therefore a pressing need for the development of improved antiplatelet agents exists. Three antiplatelet agents currently under investigation (prasugrel, AZD6140, and cangrelor) in clinical trials for the treatment of ACS appear promising.

UR - http://www.scopus.com/inward/record.url?scp=34447514184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447514184&partnerID=8YFLogxK

U2 - 10.1007/BF02938379

DO - 10.1007/BF02938379

M3 - Review article

C2 - 17601397

AN - SCOPUS:34447514184

SN - 1523-3782

VL - 9

SP - 303

EP - 311

JO - Current Cardiology Reports

JF - Current Cardiology Reports

IS - 4

ER -

New antiplatelet therapies for acute coronary syndromes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this